Download Sample
Add to CartGlobal CRISPR And CRISPR-Associated (Cas) Genes Market Growth, Share, Size, Trends and Forecast (2025 - 2031)
By Product;
Vector-Based Cas and DNA-Free Cas.By Application;
Genome Engineering, Disease Models, Functional Genomics, Knockdown/Activation, and Others.By End Use;
Biotechnology & Pharmaceutical Companies, Academic & Government Research Institutes, and Contract Research Organizations (CROs).By Geography;
North America, Europe, Asia Pacific, Middle East and Africa and Latin America - Report Timeline (2021 - 2031).Introduction
Global CRISPR And CRISPR-Associated (Cas) Genes Market (USD Million), 2021 - 2031
In the year 2024, the Global CRISPR And CRISPR-Associated (Cas) Genes Market was valued at USD 4,071.94 million. The size of this market is expected to increase to USD 21,037.43 million by the year 2031, while growing at a Compounded Annual Growth Rate (CAGR) of 26.4%.
The COVID-19 pandemic has significantly impacted the CRISPR market, with a surge in demand for CRISPR-based diagnostic tests due to their ability to diagnose SARS-CoV-2 infections quickly. Studies showcasing the potential of CRISPR technology in controlling and treating COVID-19, such as the research conducted by Duke Health, have contributed to a positive outlook for the market. As COVID-19 restrictions ease, the market is expected to witness growth fueled by increased research activities involving CRISPR and CRISPR-associated genes.
Investments by biotechnology companies, like Pfizer Inc.'s significant investment in clinical-stage biotech companies, underscore the growing interest in CRISPR technology for therapeutic development. These investments provide funding and access to scientific expertise, driving the development of CRISPR and associated genes and thereby supporting market growth. Additionally, rising genomics research and development activities, demonstrated by clinical data presentations like those by Vertex and CRISPR Therapeutics, further contribute to market expansion.
The high burden of cancer and other diseases also drives market growth, as CRISPR technology plays a vital role in identifying mutations associated with various cancers. Personalized treatment options, like those enabled by CRISPR gene editing to modify immune cells for cancer therapy, offer promising avenues for disease management. However, challenges such as off-target effects and ethical concerns associated with CRISPR technology may restrain market growth over the forecast period.
The rising investment in novel therapeutics and genomics research, coupled with the potential for personalized treatment options offered by CRISPR technology, are expected to drive market growth. Despite challenges, the market is poised for expansion as the technology continues to demonstrate its potential in various therapeutic and research applications.
Global CRISPR And CRISPR-Associated (Cas) Genes Market Recent Developments
-
In December 2022, a clinical trial titled "Transplantation of CRISPR_SCD001" was sponsored by a University of California researcher to evaluate hematopoietic stem cell transplantation (HSCT) using CRISPR/Cas9 edited red blood cells for severe sickle cell disease.
-
In November 2022, MIT researchers developed PASTE, a CRISPR-based tool for inserting large DNA sequences into cells, offering potential treatment for genetic diseases.
Segment Analysis
The CRISPR-Cas product market features two primary types of Cas proteins: vector-based Cas and DNA-free Cas. Vector-based Cas involves delivering the Cas protein and guide RNA through a plasmid or viral vector, integrating it into the cell for long-term expression, making it useful in stable genome editing applications. DNA-free Cas, on the other hand, directly delivers Cas protein and guide RNA as a ribonucleoprotein complex (RNP) without any DNA, reducing the risk of off-target effects and integration. This DNA-free approach is favored for applications where precise, temporary edits are needed, ensuring safety and minimizing genetic alterations beyond the intended targets.
CRISPR-Cas systems have numerous applications, including genome engineering, disease model creation, functional genomics studies, and gene knockdown/activation. Genome engineering is a prominent application where Cas proteins enable targeted modifications, critical for gene therapy research and crop improvement. Disease models generated with CRISPR help in understanding complex diseases and testing potential treatments. Functional genomics utilizes Cas systems to investigate gene function across various pathways, while gene knockdown and activation applications allow researchers to modulate gene expression levels, gaining insight into regulatory processes. These diverse applications illustrate the versatility of CRISPR-Cas in both research and applied biotechnology.
The primary end users of CRISPR-Cas technology are biotechnology and pharmaceutical companies, academic and government research institutes, and contract research organizations (CROs). Biotechnology and pharmaceutical companies leverage CRISPR for drug discovery and development, while academic and government research institutes focus on basic research, studying gene function and exploring new therapeutic approaches. CROs provide outsourced research services, offering CRISPR expertise to support clients in various industries. Together, these end users drive advancements in CRISPR-based research, contributing to innovative solutions across healthcare, agriculture, and environmental sciences.
Global CRISPR And CRISPR-Associated (Cas) Genes Segment Analysis
In this report, the Global CRISPR And CRISPR-Associated (Cas) Genes Market has been segmented by Product, Application, End Use and Geography.
Global CRISPR And CRISPR-Associated (Cas) Genes Market, Segmentation by Product
The Global CRISPR And CRISPR-Associated (Cas) Genes Market has been segmented by Product into Vector-based Cas and DNA-free Cas.
The product segment dominated the market due to the availability of advanced technologies like CRISPR gene editing kits. These kits offer versatile solutions for genome editing, including gene knockouts, selective genome cleavage, and genome engineering. The increasing demand for precise and efficient genome editing tools has propelled the growth of the product segment, accounting for the highest market share.
The service segment is expected to witness rapid growth driven by increased investments in gene editing-based research and development. As more applications for gene editing emerge, there is a growing need for specialized services to support these endeavors. For example, initiatives like the one funded by The British Heart Foundation to develop gene-editing treatments for inherited heart diseases highlight the expanding scope of gene editing services. The advent of CRISPR technology has unlocked numerous possibilities in combating various diseases, including cardiovascular conditions, driving the demand for gene editing services worldwide.
Global CRISPR And CRISPR-Associated (Cas) Genes Market, Segmentation by Application
The Global CRISPR And CRISPR-Associated (Cas) Genes Market has been segmented by Application into Genome Engineering, Disease Models, Functional Genomics, Knockdown/Activation and Others.
The dominance of the biomedical applications segment in the CRISPR market underscores the technology's profound impact on biological sciences. The increasing utilization of CRISPR gene-editing technologies across various biological fields has led to significant revenue growth within this segment. Advancements in delivery methods, such as the introduction of nanocarriers, have enhanced the effectiveness and specificity of CRISPR technology, further driving its adoption. Moreover, the surge in studies and publications utilizing CRISPR for genome modifications in human somatic cells and induced pluripotent stem cells highlights its growing prominence in biomedical research. Additionally, the availability of commercial kits and services provided by companies specializing in CRISPR technology further supports researchers in this domain, contributing to the segment's continued dominance in the market.
Meanwhile, the agricultural segment is poised for rapid growth, fueled by the increasing adoption of CRISPR technology in agricultural production. The integration of innovative breeding technology, facilitated by CRISPR/Cas9, has enabled the development of nutrition-rich foods and enhanced agricultural yields. For instance, researchers have successfully employed CRISPR/Cas9 technology to induce mutations in genes associated with flowering suppression in tomatoes, resulting in rapid flowering and improved compact growth, ultimately leading to earlier yields. Such advancements in agricultural biotechnology highlight the potential of CRISPR technology to revolutionize food production and address global challenges related to food security and nutrition. As the adoption of CRISPR technology continues to expand in agriculture, driven by its proven efficacy and potential benefits, the segment is expected to register substantial growth in the coming years.
Global CRISPR And CRISPR-Associated (Cas) Genes Market, Segmentation by End Use
The Global CRISPR And CRISPR-Associated (Cas) Genes Market has been segmented by End Use into Biotechnology & Pharmaceutical Companies, Academic & Government Research Institutes and Contract Research Organizations (CROs).
Biotechnology and pharmaceutical companies emerged as the dominant players in the CRISPR & Cas Genes market, accounting for nearly half of the total revenue share. This segment is projected to maintain its rapid growth trajectory throughout the forecast period, driven by pharmaceutical companies' increasing utilization of CRISPR technologies for various applications. These technologies enable pharmaceutical companies to swiftly identify and validate new therapeutic targets, accelerating the drug discovery and development process. Additionally, CRISPR facilitates the creation of more accurate biological models for human diseases, enabling researchers to study disease mechanisms and evaluate potential treatments more efficiently. The market is further propelled by the growing number of biotechnology firms leveraging gene modification techniques for both research and commercial purposes, underscoring the widespread adoption of CRISPR technology across the biopharmaceutical industry.
There is a significant demand for CRISPR-based gene-editing methods in the development of innovative medicines, particularly in the field of cell and gene therapies. CRISPR's versatility extends beyond traditional gene editing, as its core architecture has been adapted to target the epigenome, enabling researchers to control gene expression and manipulate epigenetic inheritance. For example, in April 2021, researchers from the Massachusetts Institute of Technology and the University of California developed a CRISPR on-off switch capable of regulating gene expression with precision. Such advancements expand the utility of CRISPR technology in therapeutic applications, paving the way for the development of novel treatments for a wide range of diseases. As the pharmaceutical and biotechnology sectors continue to invest in CRISPR-based research and development, the market is poised for sustained growth and innovation in the coming years.
Global CRISPR And CRISPR-Associated (Cas) Genes Market, Segmentation by Geography
In this report, the Global CRISPR And CRISPR-Associated (Cas) Genes Market has been segmented by Geography into five regions; North America, Europe, Asia Pacific, Middle East and Africa and Latin America.
Global CRISPR And CRISPR-Associated (Cas) Genes Market Share (%), by Geographical Region, 2024
North America emerged as the leading market for CRISPR & Cas Genes, capturing the highest revenue share of 38.37%. The region's dominance can be attributed to the robust biopharmaceutical research and development landscape, coupled with the active involvement of several pharmaceutical corporations in the development of novel therapeutics. For instance, Merck KGaA received U.S. approval for two of its CRISPR Cas9-driven gene-editing patents in May 2020, reflecting the region's commitment to advancing CRISPR technology for therapeutic applications. With ongoing investments and advancements in biopharmaceutical R&D, North America is poised to maintain its prominent position in the global CRISPR market.
The Asia Pacific region is expected to witness the fastest compound annual growth rate (CAGR) of 17.53% during the forecast period. Government initiatives aimed at fostering research and development to develop novel treatments play a crucial role in driving market expansion in the region. Countries like Japan and China are at the forefront of these efforts, with significant investments in biotechnology and pharmaceutical innovation. For example, in March 2021, Japanese biotech company Setsuro Tech obtained a patent for CRISPR-Cas9 technology, enabling the creation of animal and cell models using advanced CRISPR technologies. Such initiatives are anticipated to accelerate the adoption of CRISPR technology in the Asia Pacific region, leading to substantial revenue generation opportunities. As the region continues to invest in biotechnology and embrace CRISPR innovation, it is poised to emerge as a key growth driver in the global CRISPR market.
Market Trends
This report provides an in depth analysis of various factors that impact the dynamics of Global CRISPR And CRISPR-Associated (Cas) Genes Market. These factors include; Market Drivers, Restraints and Opportunities Analysis.
Drivers, Restraints and Opportunities
Drivers
- Increasing Research Activities
- Rising Investment by Biotechnology Companies
-
High Burden of Cancer and Chronic Diseases: The high prevalence of cancer and chronic diseases globally underscores the urgent need for innovative therapeutic approaches, driving the demand for CRISPR-based therapies. CRISPR technology has emerged as a promising tool in the fight against cancer, with its ability to precisely target and edit genes associated with tumor growth and metastasis. This potential for targeted gene editing offers new avenues for developing personalized treatment strategies tailored to individual patients' genetic profiles, thereby enhancing efficacy and minimizing adverse effects.
Clinical trials and research activities are actively exploring the application of CRISPR technology in cancer treatment, showcasing its versatility and effectiveness. These studies aim to identify specific genetic mutations driving cancer progression and develop CRISPR-based interventions to disrupt tumor growth pathways. Additionally, CRISPR enables researchers to engineer immune cells to recognize and attack cancer cells more effectively, leading to improved therapeutic outcomes and patient survival rates.
The versatility of CRISPR technology extends beyond cancer to address various chronic diseases, including genetic disorders, neurodegenerative diseases, and cardiovascular conditions. By targeting disease-causing genetic mutations with precision, CRISPR-based therapies hold promise for providing long-term solutions and improving patients' quality of life. As research in this field continues to advance and clinical trials yield promising results, the demand for CRISPR-based therapies is expected to escalate, driving further market growth and innovation.
Restraints
- Ethical and Regulatory Concerns
- Off-Target Effects and Safety Concerns
-
Intellectual Property Disputes: The landscape of CRISPR patents is characterized by complexity and ongoing disputes, reflecting the intense competition among academic institutions and biotechnology companies to secure intellectual property rights in this rapidly evolving field. These disputes often involve claims of priority for key discoveries, such as the identification of CRISPR/Cas systems and their applications in gene editing. As a result, the patent landscape is fragmented, with multiple patents granted to different entities for various aspects of CRISPR technology, including methods, compositions, and applications.
The legal uncertainties stemming from these patent disputes and licensing issues present significant challenges for researchers, developers, and investors in the CRISPR field. Ambiguities in patent ownership and licensing agreements may hinder collaborative efforts, limit access to essential CRISPR technologies, and increase the costs associated with research and development. Moreover, the potential for patent infringement litigation adds further complexity and risks to commercialization efforts, potentially deterring investment and stifling innovation in CRISPR-based therapies and applications. Addressing these intellectual property challenges will require collaboration, transparency, and clear regulatory guidelines to foster a conducive environment for innovation and investment in the CRISPR field.
Opportunities
- Therapeutic Applications
- Agricultural Biotechnology
-
Diagnostic and Research Tools: The increasing utilization of CRISPR-Cas systems in molecular biology research and diagnostics has sparked a demand for innovative CRISPR-based products tailored to various applications. Companies operating in this space have an opportunity to capitalize on this growing demand by developing a diverse range of research reagents, kits, and diagnostic assays that leverage the power of CRISPR technology. These products can facilitate gene editing experiments, enabling researchers to precisely manipulate genomic sequences for a deeper understanding of gene function and regulation. Additionally, CRISPR-based tools can enhance functional genomics studies by allowing researchers to elucidate the roles of specific genes in biological processes, disease pathways, and drug responses.
The development of CRISPR-based diagnostic assays holds significant promise for the detection and diagnosis of genetic disorders, infectious diseases, and cancer. Companies can innovate in this area by creating highly sensitive and specific diagnostic tests that leverage CRISPR technology for accurate detection of genetic mutations, pathogens, and biomarkers associated with various diseases. As the demand for efficient and reliable diagnostic tools continues to rise, there are abundant opportunities for market expansion and diversification of product offerings in the CRISPR-based diagnostics segment. By leveraging the versatility and precision of CRISPR technology, companies can meet the evolving needs of researchers and healthcare professionals, ultimately contributing to advancements in molecular biology research and improved patient care.
Competitive Landscape Analysis
Key players in Global CRISPR And CRISPR-Associated (Cas) Genes Market include
- Addgene
- AstraZeneca
- Bio-Rad Laboratories, Inc
- Caribou Biosciences, Inc
- Cellectis, Cibus
- CRISPR THERAPEUTICS
- Editas Medicine
- Egenesis Inc.
- GE Healthcare Dharmacon Inc
In this report, the profile of each market player provides following information:
- Company Overview and Product Portfolio
- Key Developments
- Financial Overview
- Strategies
- Company SWOT Analysis
- Introduction
- Research Objectives and Assumptions
- Research Methodology
- Abbreviations
- Market Definition & Study Scope
- Executive Summary
- Market Snapshot, By Product
- Market Snapshot, By Application
- Market Snapshot, By End Use
- Market Snapshot, By Region
- Global CRISPR And CRISPR-Associated (Cas) Genes Market Dynamics
- Drivers, Restraints and Opportunities
- Drivers
- Increasing Research Activities
- Rising Investment by Biotechnology Companies
- High Burden of Cancer and Chronic Diseases
- Restraints
- Ethical and Regulatory Concerns
- Off-Target Effects and Safety Concerns
- Intellectual Property Disputes
- Opportunities
- Therapeutic Applications
- Agricultural Biotechnology
- Diagnostic and Research Tools
- Drivers
- PEST Analysis
- Political Analysis
- Economic Analysis
- Social Analysis
- Technological Analysis
- Porter's Analysis
- Bargaining Power of Suppliers
- Bargaining Power of Buyers
- Threat of Substitutes
- Threat of New Entrants
- Competitive Rivalry
- Drivers, Restraints and Opportunities
- Market Segmentation
- Global CRISPR And CRISPR-Associated (Cas) Genes Market, By Product, 2021 - 2031 (USD Million)
- Vector-based Cas
- DNA-free Cas
- Global CRISPR And CRISPR-Associated (Cas) Genes Market, By Application, 2021 - 2031 (USD Million)
- Genome Engineering
- Disease Models
- Functional Genomics
- Knockdown/Activation
- Others
- Global CRISPR And CRISPR-Associated (Cas) Genes Market, By End Use, 2021 - 2031 (USD Million)
- Biotechnology & Pharmaceutical Companies
- Academic & Government Research Institutes
- Contract Research Organizations (CROs)
- Global CRISPR And CRISPR-Associated (Cas) Genes Market, By Geography, 2021 - 2031 (USD Million)
- North America
- United States
- Canada
- Europe
- Germany
- United Kingdom
- France
- Italy
- Spain
- Nordic
- Benelux
- Rest of Europe
- Asia Pacific
- Japan
- China
- India
- Australia & New Zealand
- South Korea
- ASEAN (Association of South East Asian Countries)
- Rest of Asia Pacific
- Middle East & Africa
- GCC
- Israel
- South Africa
- Rest of Middle East & Africa
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- North America
- Global CRISPR And CRISPR-Associated (Cas) Genes Market, By Product, 2021 - 2031 (USD Million)
- Competitive Landscape
- Company Profiles
- Addgene
- AstraZeneca
- Bio-Rad Laboratories, Inc
- Caribou Biosciences, Inc
- Cellectis, Cibus
- CRISPR THERAPEUTICS
- Editas Medicine
- Egenesis Inc.
- GE Healthcare Dharmacon Inc
- Company Profiles
- Analyst Views
- Future Outlook of the Market